Difference between revisions of "Team:Linkoping Sweden/Description"

 
(64 intermediate revisions by 5 users not shown)
Line 1: Line 1:
<!--{{Linkoping_Sweden/Header}}-->
+
{{Linkoping_Sweden/Style}}
 +
{{Linkoping_Sweden/Header}}
  
 
<html>
 
<html>
 
+
       
<head>
+
<style>
+
body {margin:0;}
+
 
+
.topnav {
+
  overflow: hidden;
+
  background-color: #019966;
+
}
+
 
+
.topnav a {
+
  float: left;
+
  display: block;
+
  color: white;
+
  text-align: center;
+
  padding: 14px 16px;
+
  text-decoration: none;
+
  font-size: 17px;
+
  font-weight: bold;
+
}
+
 
+
.topnav a:hover {
+
  background-color: white;
+
  color: #019966;
+
  <!--border: 2px solid #019966;-->
+
}
+
 
+
.topnav .icon {
+
  display: none;
+
}
+
 
+
@media screen and (max-width: 600px) {
+
  .topnav a:not(:first-child) {display: none;}
+
  .topnav a.icon {
+
    float: right;
+
    display: block;
+
  }
+
}
+
 
+
@media screen and (max-width: 600px) {
+
  .topnav.responsive {position: relative;}
+
  .topnav.responsive .icon {
+
    position: absolute;
+
    right: 0;
+
    top: 0;
+
  }
+
  .topnav.responsive a {
+
    float: none;
+
    display: block;
+
    text-align: left;
+
  }
+
 
+
}
+
</style>
+
</head>
+
 
<body>
 
<body>
<nav>
+
<div class="topnav" id="myTopnav">
+
  <a href="#home">Home</a>
+
    <div class="menu-content">
+
<div id="flex-wrapper">
      <a href="https://2017.igem.org/Team:Linkoping_Sweden/Project">The Project</a>
+
<div class="flex-container">  
      <a href="https://2017.igem.org/Team:Linkoping_Sweden/Description">Project Description</a>
+
    </div>
+
<!--
  <a href="#news">News</a>
+
Här läggs all content! content (p h2 img a osv.) ska placeras i dessa: flex-text-__ och flex-img-__ .
  <a href="#contact">Contact</a>
+
Om content ska placeras brevid varandra läggs föregående taggar i dessa: flex-sidebyside(-reverse), flex-flipper .
  <a href="#about">About</a>
+
Läs mer om vad dessa gör på drive i dokumentet: igem2017/hemsida/betasidan/variabelnamn.
  <a href="javascript:void(0);" style="font-size:15px;" class="icon" onclick="myFunction()">&#9776;</a>
+
-->
</div>
+
 
+
<Article class="flex-text-100">
<div style="padding-left:16px">
+
<h1> Project Description</h1>
  <h2>Responsive Topnav Example</h2>
+
<hr>
  <p>Resize the browser window to see how it works.</p>
+
</article>
</div>
+
 
+
<div class="flex-flipper">
<script>
+
<article class="flex-text-70">
function myFunction() {
+
<p>
    var x = document.getElementById("myTopnav");
+
Amyloid-Beta and Tau are proteins which are known to be linked to the development of Alzheimer's disease, though the cause of the disease is still unknown [1]. They are both found in the brain in and around our neurons, and during Alzheimer's disease they accumulate to form plaques and tangles [2, 3]. The study of these aggregates are often done by staining them(4), which in turn demands an amount of the plaques great enough for staining. To instead study the early development of the aggregates a new method has to be developed. This could be studied by fusing a fluorescent markers like Green Fluorescent Protein (GFP) with the aggregation prone proteins. The problem is that when these marker are combined with the aggregation prone protein they become hard to express in Escherichia coli [5]. <u>Therefore this year’s project is to optimize the expression the fusion proteins containing a fluorescent marker and amyloid-beta or tau in E. Coli. </u>
    if (x.className === "topnav") {
+
</br></br>
        x.className += " responsive";
+
To optimize the expression of the proteins we will be using overexpressed chaperones. Chaperones are proteins that can help other proteins to fold into their native three-dimensional shape, for example by dissolving aggregates and guiding both unfolded and misfolded proteins to their correctly folded form [6]. During our project we will be using four different chaperones and we will see how different combinations of these affect the expression of Amyloid-beta and Tau respectively.
    } else {
+
</p>
        x.className = "topnav";
+
</article>
    }
+
<article class="flex-text-30" style = "border: solid 2px #019667; border-radius: 4px; padding: 0.8% 0.8%;">
}
+
<h4>Quick facts about Alzheimer's disease:</h4>
</script>
+
<br>
</nav>
+
</body>
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
<!-- -----------------------------------------------------------------------------
+
 
+
 
+
<div class="column full_size">
+
<h1>Description</h1>
+
 
+
<p>Tell us about your project, describe what moves you and why this is something important for your team.</p>
+
 
+
 
+
<h5>What should this page contain?</h5>
+
 
<ul>
 
<ul>
<li> A clear and concise description of your project.</li>
+
<li>Around 60-70 % of people with dementia have Alzheimer’s disease.</li>
<li>A detailed explanation of why your team chose to work on this particular project.</li>
+
<li>Around 1 in 100 has Alzheimer’s disease in Sweden.</li>
<li>References and sources to document your research.</li>
+
<li>The cause of Alzheimer’s disease is formation of protein accumulations in the brain.</li>
<li>Use illustrations and other visual resources to explain your project.</li>
+
<li>Alzheimer’s disease is a fatal disease.</li>
 +
<li>Read more <a href="https://2017.igem.org/Team:Linkoping_Sweden/AlzheimersDisease"> here </a> </li>
 
</ul>
 
</ul>
 +
</article>
 +
<!--<div class="flex-text-30">
 +
<a class="content-button" href=""> Read more about alzheimer here </a>
 +
</div> -->
 +
</div>
 +
 +
 +
<div class="flex-flipper">
 +
<article class="flex-text-70">
 +
<p>
 +
The chaperones we will study are GroEL, GroES, DnaK and Trigger factor. GroEL and GroES helps unfolded and misfolded proteins to fold correctly [7]. DnaK helps with disaggregating and with unfolding of misfolded proteins [6]. And Trigger factor helps the protein to remain unfolded during its synthesis [7].
  
 +
</br></br>
 +
To overexpress the chaperones in the bacteria we will use a large plasmid containing all four chaperones and give them unique positively regulated promotors, one for GroEL-GroES, one for DnaK and one for TF. The purpose of this was to easily be able to induce transcription of the specific chaperones in different combinations.
 +
</p>
 +
</article>
 +
<!--<div class="flex-text-30">
 +
<a class="content-button" href="#"> Read more about the different chaperones here </a>
 +
</div>-->
 +
</div>
 +
 +
<div class="flex-flipper">
 +
<article class="flex-text-70">
 +
<p>
 +
The fluorescent markers we will fuse our proteins with are Enhanced-GFP (EGFP) and mNeonGreen. EGFP are a variation of GFP and mNeonGreen is derived from LanYFP [8]. mNeonGreen itself foldes much faster than EGFP and therefore one of these two could be expressed more easily than the other.
 +
</br></br>
 +
For every one of alzheimer-fluorescent fusion protein we will create a plasmid resulting in 4 combinations. These 4 plasmids will use a fourth promotor so that we can control this expression as well.
 +
</p>
 +
</article>
 +
<!--<div class="flex-text-30">
 +
<a class="content-button" href="#"> Read more about the fusion proteins here </a>
 +
</div>-->
 +
</div>
  
</div>
+
<div class="flex-flipper">
 +
                                <article class="flex-text-100">
 +
<p>
 +
If we succeeds with our project we  will create a model for successfully expressing these aggregate prone fusion proteins. The future of the project would then be to apply this model to other troublesome proteins and get a deeper knowledge about how the chaperones handle them.
 +
</p>
 +
</article>
 +
</div>
  
<div class="column full_size" >
+
<div class="flex-flipper">
 +
<article class="flex-text-100">
 +
<h3> Our work process </h3>
 +
<p>
 +
The overview of the project is summarized in figure 1 below. As can be seen in the figure, chaperones and conditions will be tested in a screening process, with the purpose to find the best setup for further detailed studies. The detailed studies will involve modeling with systems biology, where the modeling team will give suggestions on what the laboratory team shall do to achieve the desired task. The flow of data between the laboratory and the modeling team will eventually result in the final data, with is the optimized setup for the expression of our peptides.
 +
</p>
 +
</article>
 +
</div>
  
<h5>Advice on writing your Project Description</h5>
+
<div class="flex-img-100">
 +
<img alt="project flow-chart" class="img-center" src="https://static.igem.org/mediawiki/2017/d/dd/T--Linkoping_Sweden--Flowchart_green.png">
 +
</div>
 +
 +
<article class="flex-text-100 text-center">
 +
<p class="text-center"> <i> Figure 1. An overviewing design of the project. </i> </p>
 +
</article>
 +
 +
<article class="flex-text-100 text-break">
 +
</br>
 +
<hr>
 +
                                        <h3> Sources </h3>
 +
<p class="text-small">
 +
1. Alzheimerfonden. Alzheimers sjukdom [Internet]. Cited 2017-06-15. Available from: http://www.alzheimerfonden.se/om_demens/alzheimers_sjukdom [in swedish]
 +
</br> 2. Alzheimerfonden. Lexikon för Alzheimers sjukdom och andra demenssjukdomar [Internet]. Cited 2017-06-15. Available from: http://www.alzheimerfonden.se/om_demens/lexikon [in swedish]
 +
</br> 3. Bloom GS. Amyloid-β and TauThe Trigger and Bullet in Alzheimer Disease Pathogenesis. JAMA Neurol. 2014;71(4):505-508. doi:10.1001/jamaneurol.2013.5847
 +
</br> 4. Baltes C, Princz-Kranz F, Rudin M, Mueggler T. Detecting Amyloid-β Plaques in Alzheimer’s Disease BT  - Magnetic Resonance Neuroimaging: Methods and Protocols. In: Modo M, Bulte JWM, editors. Totowa, NJ: Humana Press; 2011. p. 511–33. Available from: https://doi.org/10.1007/978-1-61737-992-5_26
 +
</br> 5. Kim, W., & Hecht, M. H. (2008). Mutations Enhance the Aggregation Propensity of the Alzheimer’s Aβ Peptide. Journal of Molecular Biology. http://doi.org/10.1016/j.jmb.2007.12.079
 +
</br> 6. Schröder, H., Langer, T., Hartl, F. U., & Bukau, B. (1993). DnaK, DnaJ and GrpE form a cellular chaperone machinery capable of repairing heat-induced protein damage. The EMBO Journal, 12(11), 4137–44. Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=413706&tool=pmcentrez&rendertype=abstract
 +
</br> 7. Powers, E. T., Powers, D. L., & Gierasch, L. M. (2012). FoldEco: A Model for Proteostasis in E. coli. Cell Reports, 1(3), 265–276. http://doi.org/10.1016/j.celrep.2012.02.011
 +
</br> 8. Shaner, N. C., Lambert, G. G., Chammas, A., Ni, Y., Cranfill, P. J., Baird, M. A., … Wang, J. (2013). A bright monomeric green fluorescent protein derived from Branchiostoma lanceolatum. Nature Methods, 10(5), 407–409. http://doi.org/10.1038/nmeth.2413
 +
</p>
 +
</article>
 +
</div> <!-- end of flex-container -->
 +
<aside class="aside aside-l"> </aside>
 +
<aside class="aside aside-r"> </aside>
  
<p>
+
We encourage you to put up a lot of information and content on your wiki, but we also encourage you to include summaries as much as possible. If you think of the sections in your project description as the sections in a publication, you should try to be consist, accurate and unambiguous in your achievements.
+
</body>
</p>
+
 
+
<p>
+
Judges like to read your wiki and know exactly what you have achieved. This is how you should think about these sections; from the point of view of the judge evaluating you at the end of the year.
+
</p>
+
 
+
</div>
+
 
+
 
+
<div class="column half_size" >
+
 
+
<h5>References</h5>
+
<p>iGEM teams are encouraged to record references you use during the course of your research. They should be posted somewhere on your wiki so that judges and other visitors can see how you thought about your project and what works inspired you.</p>
+
 
+
</div>
+
 
+
 
+
<div class="column half_size" >
+
<h5>Inspiration</h5>
+
<p>See how other teams have described and presented their projects: </p>
+
 
+
<ul>
+
<li><a href="https://2016.igem.org/Team:Imperial_College/Description">2016 Imperial College</a></li>
+
<li><a href="https://2016.igem.org/Team:Wageningen_UR/Description">2016 Wageningen UR</a></li>
+
<li><a href="https://2014.igem.org/Team:UC_Davis/Project_Overview"> 2014 UC Davis</a></li>
+
<li><a href="https://2014.igem.org/Team:SYSU-Software/Overview">2014 SYSU Software</a></li>
+
</ul>
+
</div>
+
------------------------------------------------------------------------------- -->
+
  
 
</html>
 
</html>
 
{{Linkoping_Sweden/Footer}}
 
{{Linkoping_Sweden/Footer}}

Latest revision as of 13:47, 31 October 2017

Project Description


Amyloid-Beta and Tau are proteins which are known to be linked to the development of Alzheimer's disease, though the cause of the disease is still unknown [1]. They are both found in the brain in and around our neurons, and during Alzheimer's disease they accumulate to form plaques and tangles [2, 3]. The study of these aggregates are often done by staining them(4), which in turn demands an amount of the plaques great enough for staining. To instead study the early development of the aggregates a new method has to be developed. This could be studied by fusing a fluorescent markers like Green Fluorescent Protein (GFP) with the aggregation prone proteins. The problem is that when these marker are combined with the aggregation prone protein they become hard to express in Escherichia coli [5]. Therefore this year’s project is to optimize the expression the fusion proteins containing a fluorescent marker and amyloid-beta or tau in E. Coli.

To optimize the expression of the proteins we will be using overexpressed chaperones. Chaperones are proteins that can help other proteins to fold into their native three-dimensional shape, for example by dissolving aggregates and guiding both unfolded and misfolded proteins to their correctly folded form [6]. During our project we will be using four different chaperones and we will see how different combinations of these affect the expression of Amyloid-beta and Tau respectively.

Quick facts about Alzheimer's disease:


  • Around 60-70 % of people with dementia have Alzheimer’s disease.
  • Around 1 in 100 has Alzheimer’s disease in Sweden.
  • The cause of Alzheimer’s disease is formation of protein accumulations in the brain.
  • Alzheimer’s disease is a fatal disease.
  • Read more here

The chaperones we will study are GroEL, GroES, DnaK and Trigger factor. GroEL and GroES helps unfolded and misfolded proteins to fold correctly [7]. DnaK helps with disaggregating and with unfolding of misfolded proteins [6]. And Trigger factor helps the protein to remain unfolded during its synthesis [7].

To overexpress the chaperones in the bacteria we will use a large plasmid containing all four chaperones and give them unique positively regulated promotors, one for GroEL-GroES, one for DnaK and one for TF. The purpose of this was to easily be able to induce transcription of the specific chaperones in different combinations.

The fluorescent markers we will fuse our proteins with are Enhanced-GFP (EGFP) and mNeonGreen. EGFP are a variation of GFP and mNeonGreen is derived from LanYFP [8]. mNeonGreen itself foldes much faster than EGFP and therefore one of these two could be expressed more easily than the other.

For every one of alzheimer-fluorescent fusion protein we will create a plasmid resulting in 4 combinations. These 4 plasmids will use a fourth promotor so that we can control this expression as well.

If we succeeds with our project we will create a model for successfully expressing these aggregate prone fusion proteins. The future of the project would then be to apply this model to other troublesome proteins and get a deeper knowledge about how the chaperones handle them.

Our work process

The overview of the project is summarized in figure 1 below. As can be seen in the figure, chaperones and conditions will be tested in a screening process, with the purpose to find the best setup for further detailed studies. The detailed studies will involve modeling with systems biology, where the modeling team will give suggestions on what the laboratory team shall do to achieve the desired task. The flow of data between the laboratory and the modeling team will eventually result in the final data, with is the optimized setup for the expression of our peptides.

project flow-chart

Figure 1. An overviewing design of the project.



Sources

1. Alzheimerfonden. Alzheimers sjukdom [Internet]. Cited 2017-06-15. Available from: http://www.alzheimerfonden.se/om_demens/alzheimers_sjukdom [in swedish]
2. Alzheimerfonden. Lexikon för Alzheimers sjukdom och andra demenssjukdomar [Internet]. Cited 2017-06-15. Available from: http://www.alzheimerfonden.se/om_demens/lexikon [in swedish]
3. Bloom GS. Amyloid-β and TauThe Trigger and Bullet in Alzheimer Disease Pathogenesis. JAMA Neurol. 2014;71(4):505-508. doi:10.1001/jamaneurol.2013.5847
4. Baltes C, Princz-Kranz F, Rudin M, Mueggler T. Detecting Amyloid-β Plaques in Alzheimer’s Disease BT - Magnetic Resonance Neuroimaging: Methods and Protocols. In: Modo M, Bulte JWM, editors. Totowa, NJ: Humana Press; 2011. p. 511–33. Available from: https://doi.org/10.1007/978-1-61737-992-5_26
5. Kim, W., & Hecht, M. H. (2008). Mutations Enhance the Aggregation Propensity of the Alzheimer’s Aβ Peptide. Journal of Molecular Biology. http://doi.org/10.1016/j.jmb.2007.12.079
6. Schröder, H., Langer, T., Hartl, F. U., & Bukau, B. (1993). DnaK, DnaJ and GrpE form a cellular chaperone machinery capable of repairing heat-induced protein damage. The EMBO Journal, 12(11), 4137–44. Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=413706&tool=pmcentrez&rendertype=abstract
7. Powers, E. T., Powers, D. L., & Gierasch, L. M. (2012). FoldEco: A Model for Proteostasis in E. coli. Cell Reports, 1(3), 265–276. http://doi.org/10.1016/j.celrep.2012.02.011
8. Shaner, N. C., Lambert, G. G., Chammas, A., Ni, Y., Cranfill, P. J., Baird, M. A., … Wang, J. (2013). A bright monomeric green fluorescent protein derived from Branchiostoma lanceolatum. Nature Methods, 10(5), 407–409. http://doi.org/10.1038/nmeth.2413